Edition:
India

Natus Medical Inc (BABY.OQ)

BABY.OQ on NASDAQ Stock Exchange Global Select Market

32.75USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$32.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
79,332
52-wk High
$43.55
52-wk Low
$28.05

Latest Key Developments (Source: Significant Developments)

Jonathan Kennedy To Get $650,000 In 2018 As CEO Of Natus Medical
Thursday, 12 Jul 2018 

July 12 (Reuters) - Natus Medical Inc ::NATUS MEDICAL - JONATHAN KENNEDY WILL RECEIVE AN ANNUAL BASE SALARY OF $650,000 IN 2018, IN CONNECTION WITH HIS APPOINTMENT AS PRESIDENT AND CEO.  Full Article

Nox Medical Claims For Infringement By Natus Neurology
Monday, 21 May 2018 

May 21 (Reuters) - Nox Medical: :NOX MEDICAL SAYS CLAIMS FOR INFRINGEMENT BY NATUS NEUROLOGY.NOX MEDICAL - ALLEGES NATUS NEUROLOGY INFRINGED NOX MEDICAL'S PATENT COVERING BIOMETRIC CONNECTOR ON DISPOSABLE RIP BELTS.NOX MEDICAL SAYS JURY AWARDED CO DAMAGES FOR NATUS' INFRINGEMENT, AND FINDING THAT NATUS' INFRINGEMENT OF '532 PATENT WAS WILLFUL.  Full Article

Natus Medical Announces 2018 Annual And First Quarter Financial Guidance
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Natus Medical ::REVENUE IN Q4 WAS LOWER THAN EXPECTED DUE TO WEAKNESS IN OUR U.S. NEURODIAGNOSTIC BUSINESS.‍FULL YEAR AND Q1 2018 NON-GAAP GUIDANCE DOES NOT INCLUDE EXPENSES FOR U.S. MEDICAL DEVICE TAX​.DUE IN PART TO DISRUPTION FROM INTEGRATION OF COMPUTER SYSTEMS, Q4 REVENUE ALSO LOWER THAN EXPECTED AT OTOMETRICS.‍IF NOT REPEALED OR SUSPENDED, MEDICAL DEVICE TAX WILL HAVE AN ANNUAL AFTER TAX COST OF APPROXIMATELY $3.0 MILLION​.INCREASING INVESTMENTS IN KEY PRODUCT AREAS IN 2018.ANNOUNCES 2018 ANNUAL AND FIRST QUARTER FINANCIAL GUIDANCE.SEES FY 2018 NON-GAAP EARNINGS PER SHARE $1.60 TO $1.65.SEES Q1 2018 REVENUE $125 MILLION TO $127 MILLION.SEES FY 2017 REVENUE $500.5 MILLION TO $501.5 MILLION.SEES FY 2018 REVENUE $535 MILLION TO $540 MILLION.SEES Q1 2018 NON-GAAP EARNINGS PER SHARE $0.23 TO $0.24.SEES Q4 2017 REVENUE ABOUT $131 MILLION TO $132 MILLION.EXPECT OTOSCAN REVENUES TO RAMP IN SECOND HALF OF 2018.  Full Article

Natus Medical Inc reports ‍Q3 loss per share of $0.26​
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Natus Medical Inc :Natus Medical Inc - ‍Q3 2017 loss per share $0.26​.Sees FY 2017 non-GAAP earnings per share $1.72 to $1.76.Natus Medical Inc qtrly ‍adj earnings per share $0.40​.Sees Q4 2017 non-GAAP earnings per share $0.68 to $0.72.Natus Medical Inc - ‍for Q3, company reported revenue of $122.6 million, an increase of 34.9% compared to $90.9 million reported for Q3 2016​.Sees FY 2017 revenue $514.5 million to $516.5 million.Sees Q4 2017 revenue $145 million to $147 million.Q3 earnings per share view $0.38, revenue view $122.1 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $1.70, revenue view $508.7 million -- Thomson Reuters I/B/E/S.Q4 earnings per share view $0.69, revenue view $136.5 million -- Thomson Reuters I/B/E/S.  Full Article

Natus Medical CEO James Hawkins reports open market purchase of 10,000 shares
Wednesday, 28 Sep 2016 

Natus Medical Inc :Ceo james hawkins reports open market purchase of 10,000 shares of co's common stock at average price of $38.5 on september 28 - sec filing.  Full Article

Natus medical sees Q3 2016 revenue $89 mln to $91 mln
Monday, 26 Sep 2016 

Natus Medical Inc : Sees Q3 2016 revenue $89 million to $91 million . Natus enters into agreement to acquire gn otometrics; provides Q3 revenue update . Updated its Q3 2016 revenue guidance to $89 million to $91 million compared to previous guidance of $97 million to $98 million . Majority of expected Q3 revenue shortfall is due to voluntary ship hold co placed on certain products produced in seattle facility . Expect Otometrics to be accretive to 2017 earnings with a NON-GAAP contribution operating margin goal for year of 10%, 2018 goal of 20% . Remaining Q3 revenue shortfall is primarily due to lower demand in international markets . Updates q3 revenue guidance . Expects acquisition to be immediately accretive to NON-GAAP earnings . Deal for $145 million . Natus will use offshore cash and proceeds from this credit line to fund acquisition . Natus medical inc says has entered into a $150 million revolving credit agreement with JP Morgan Chase, n.a. And Citibank, n.a . Says with addition of Otometrics, anticipate Natus revenue in 2017 will reach $500 million .Q3 revenue view $97.8 million -- Thomson Reuters I/B/E/S.  Full Article

CORRECTED-Hedge fund Voce's nominees elected to Natus board

June 22 Natus Medical Inc said on Friday its stockholders had elected hedge fund Voce Capital Management's nominees to the company's board, ending a months long proxy fight.